b8
e
4e
24
1d
24
2
2d
8
3f
1f
17
1a
2d
9
Cameron J. Koch
49 16
19
1
49
2
8
1b
1d
18
79
33
1d
2 29
1d
25
33
Cameron J. Koch, Ph.D.
4dEmeritus Professor of Radiation Oncology
7
69
Department: Radiation Oncology
4
1
b
1d
46
Contact information
46
4
3
3
1d
46
185 John Morgan Building
3a 3620 Hamilton Walk
Philadelphia, PA 19104-6072
26
3a 3620 Hamilton Walk
Philadelphia, PA 19104-6072
2e
Office: 215-898-0073
32 Fax: 215-898-0090
24
99
32 Fax: 215-898-0090
24
Email:
kochc@pennmedicine.upenn.edu
12
kochc@pennmedicine.upenn.edu
18
Publications
23 a
3
2
29
23 a
Links
9f Search PubMed for articles
93 Department of Radiation Oncology Faculty Page
60 Koch Lab Webpage
c
4
b
1f
9f Search PubMed for articles
93 Department of Radiation Oncology Faculty Page
60 Koch Lab Webpage
c
13
Education:
21 a B.Sc. c
40 University of Waterloo, Ontario, Canada, 1968.
21 a M.Sc. c
40 University of Waterloo, Ontario, Canada, 1969.
21 a Ph.D. c
40 University of Waterloo, Ontario, Canada, 1972.
c
3
3
3
3
8a
Permanent link21 a B.Sc. c
40 University of Waterloo, Ontario, Canada, 1968.
21 a M.Sc. c
40 University of Waterloo, Ontario, Canada, 1969.
21 a Ph.D. c
40 University of Waterloo, Ontario, Canada, 1972.
c
2 29
21
1e
1d
24
5e
48 Measurement of radioresistant hypoxic tumor cells in vivo using:
35 •immunohistochemistry and/or flow cytometry
1f •non-invasive imaging
27 •Quantification of tissue pO2
45 •Control and measurement of oxygen concentration and thiols
2f •Quantitative Fluorescence Microscopy
54 •Oxidative damage (primarily sulfydryl to disulfide) of DNA repair systems
55 •Effects of oxygen and oxygen radicals in biological or biochemical systems
3c •Development of fluorine-based PET imaging methods
27 •Automated chemical synthesis
71 •Mechanisms of action of radiation sensitizing and radiation protecting agents (survival or DNA damage)
49 •Models for competitive reactions of radiation modifying agents
4f •Metabolism of thiols and nitroheterocyclics (including cytotoxicity)
3a •Measurement of intracellular drug concentrations
26 29
27
Description of Research Expertise
24 RESEARCH INTERESTS:48 Measurement of radioresistant hypoxic tumor cells in vivo using:
35 •immunohistochemistry and/or flow cytometry
1f •non-invasive imaging
27 •Quantification of tissue pO2
45 •Control and measurement of oxygen concentration and thiols
2f •Quantitative Fluorescence Microscopy
54 •Oxidative damage (primarily sulfydryl to disulfide) of DNA repair systems
55 •Effects of oxygen and oxygen radicals in biological or biochemical systems
3c •Development of fluorine-based PET imaging methods
27 •Automated chemical synthesis
71 •Mechanisms of action of radiation sensitizing and radiation protecting agents (survival or DNA damage)
49 •Models for competitive reactions of radiation modifying agents
4f •Metabolism of thiols and nitroheterocyclics (including cytotoxicity)
3a •Measurement of intracellular drug concentrations
26 29
23
14b Koch CJ: Invited editorial for the paper by Silvoniemi et al. "Repeatability of tumor hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer." in this issue of EJNMMI. European Journal of Nuclear Medicine and Molecular Imaging 45(2): 159-60, Feb 2018.
15e Makvandi M, Lin L, Effron SS, Lieberman BP, Anderson R-C, Xu K, Li S-H, Lee S, Hou C, Pryma DA, Koch CJ, Mach RH: PARP-1 expression quantified by [18F]FluorThanatrace: a biomarker of response to PARP inhibition adjuvant to radiation therapy. Cancer Biother Radiopharm Feb 2017.
1a1 Ralph A. Pietrofesa, Anastasia Velalopoulou, Stacey L. Lehman, Evguenia Arguiri, Pantelis Solomides, Cameron J. Koch, Om P. Mishra, Constantinos Koumenis, Thomas J. Goodwin and Melpo Christofidou-Solomidou : Novel Double-Hit Model of Radiation and Hyperoxia-Induced Oxidative Cell Damage Relevant to Space Travel. Int J Mol Sci 17(6), Jun 2016.
15c Evans SM, Putt M, Yang XY, Lustig RA, Martinez-Lage M, Williams D, Desai A, Wolf R, Brem S, Koch CJ.: Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. J Neurooncol. 127(2): 391-400, Apr 2016.
15a Lao Z, Kelly CJ, Yang XY, Jenkins WT, Toorens E, Ganguly T, Evans SM, Koch CJ.: Improved Methods to Generate Spheroid Cultures from Tumor Cells, Tumor Cells & Fibroblasts or Tumor-Fragments: Microenvironment, Microvesicles and MiRNA. PLoS One. 10(7): e0133895, Jul 24 2015.
c6 Koch CJ, Evans SM: Pharmacokinetic and pharmacodynamic modifiers of EF5 uptake and binding. J Nucl Med. 56(4): 653, Apr 2015.
bc Koch CJ, Evans SM.: Optimizing hypoxia detection and treatment strategies. Semin Nucl Med. 45(2): 163-76, Mar 2015.
145 Chang Q, Ornatsky OI, Koch CJ, Chaudary N, Marie-Egyptienne DT, Hill RP, Tanner SD, Hedley DW.: Single-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry. Int J Cancer. 136(5), Mar 1 2015.
154 Koch CJ, Lustig RA, Yang XY, Jenkins WT, Wolf RL, Martinez-Lage M, Desai A, Williams D, Evans SM.: Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients. Transl Oncol. 7(6): 752-8, Dec 2014.
2c
7
1d
1f
Selected Publications
10d Koch CJ: A Two-Component Assay for Hypoxia Incorporating Long-Term Nitroreduction and Short-Term DNA-Damage Allows Differentiation of the Three Hypoxia Sub-types. Rad Res Page: 72-87, May 10 2018.14b Koch CJ: Invited editorial for the paper by Silvoniemi et al. "Repeatability of tumor hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer." in this issue of EJNMMI. European Journal of Nuclear Medicine and Molecular Imaging 45(2): 159-60, Feb 2018.
15e Makvandi M, Lin L, Effron SS, Lieberman BP, Anderson R-C, Xu K, Li S-H, Lee S, Hou C, Pryma DA, Koch CJ, Mach RH: PARP-1 expression quantified by [18F]FluorThanatrace: a biomarker of response to PARP inhibition adjuvant to radiation therapy. Cancer Biother Radiopharm Feb 2017.
1a1 Ralph A. Pietrofesa, Anastasia Velalopoulou, Stacey L. Lehman, Evguenia Arguiri, Pantelis Solomides, Cameron J. Koch, Om P. Mishra, Constantinos Koumenis, Thomas J. Goodwin and Melpo Christofidou-Solomidou : Novel Double-Hit Model of Radiation and Hyperoxia-Induced Oxidative Cell Damage Relevant to Space Travel. Int J Mol Sci 17(6), Jun 2016.
15c Evans SM, Putt M, Yang XY, Lustig RA, Martinez-Lage M, Williams D, Desai A, Wolf R, Brem S, Koch CJ.: Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. J Neurooncol. 127(2): 391-400, Apr 2016.
15a Lao Z, Kelly CJ, Yang XY, Jenkins WT, Toorens E, Ganguly T, Evans SM, Koch CJ.: Improved Methods to Generate Spheroid Cultures from Tumor Cells, Tumor Cells & Fibroblasts or Tumor-Fragments: Microenvironment, Microvesicles and MiRNA. PLoS One. 10(7): e0133895, Jul 24 2015.
c6 Koch CJ, Evans SM: Pharmacokinetic and pharmacodynamic modifiers of EF5 uptake and binding. J Nucl Med. 56(4): 653, Apr 2015.
bc Koch CJ, Evans SM.: Optimizing hypoxia detection and treatment strategies. Semin Nucl Med. 45(2): 163-76, Mar 2015.
145 Chang Q, Ornatsky OI, Koch CJ, Chaudary N, Marie-Egyptienne DT, Hill RP, Tanner SD, Hedley DW.: Single-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry. Int J Cancer. 136(5), Mar 1 2015.
154 Koch CJ, Lustig RA, Yang XY, Jenkins WT, Wolf RL, Martinez-Lage M, Desai A, Williams D, Evans SM.: Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients. Transl Oncol. 7(6): 752-8, Dec 2014.
2c